H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Nemaura Medical to $2.50 from $7 and keeps a Buy rating on the shares. The firm expects the company to ramp up revenue via global partnerships in the coming years. but says its original projections for the sales trajectory may be too optimistic.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NMRD:
- Nemaura Medical Announces SFDA Approval of sugarBEAT®
- Nemaura Medical announces SFDA approval of sugarBEAT
- Nemaura Medical reports Q1 EPS (9c) vs. (16c) last year
- Nemaura Medical Secures $6.5m in Non-Dilutive Funding
- Nemaura Medical reports 2023 EPS (57c), consensus (53c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue